Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: a Target Trial Emulation
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 912
- Registration Number
- NCT06740552
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
YN001-004 in Patients With Coronary Atherosclerosis in Australia
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Beijing Inno Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06700720
- Locations
- 🇦🇺
Canberra Hospital, Canberra, Australian Capital Territory, Australia
🇦🇺Core Research Group Pty Ltd, Milton, Queesland, Australia
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Beijing Luhe Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06364124
- Locations
- 🇨🇳
Beijing luhe hospital, Beijing, China
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT06284564
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Target Recruit Count
- 20
- Registration Number
- NCT06231459
- Locations
- 🇲🇽
National Medical Center "20 de Noviembre", ISSSTE, Mexico City, Mexico
Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 80
- Registration Number
- NCT06134635
Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Region Stockholm
- Target Recruit Count
- 8
- Registration Number
- NCT06140095
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 44
- Registration Number
- NCT06081153
Rosuvastatin and Evolocumab for Coronary Artery Disease
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 195
- Registration Number
- NCT05984953
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Xiang Xie
- Target Recruit Count
- 620
- Registration Number
- NCT05976893
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.